JPS61172822A - Ionized calcium preparation for oral administration containing electrolyzed oyster shell - Google Patents

Ionized calcium preparation for oral administration containing electrolyzed oyster shell

Info

Publication number
JPS61172822A
JPS61172822A JP1360885A JP1360885A JPS61172822A JP S61172822 A JPS61172822 A JP S61172822A JP 1360885 A JP1360885 A JP 1360885A JP 1360885 A JP1360885 A JP 1360885A JP S61172822 A JPS61172822 A JP S61172822A
Authority
JP
Japan
Prior art keywords
ionized calcium
oyster shell
electrolyzed
preparation
calcium
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP1360885A
Other languages
Japanese (ja)
Other versions
JPH0113691B2 (en
Inventor
Ranko Inoue
井上 蘭子
Toshio Ueno
利夫 上野
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Fujix Corp
Original Assignee
Fujix Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Fujix Corp filed Critical Fujix Corp
Priority to JP1360885A priority Critical patent/JPS61172822A/en
Publication of JPS61172822A publication Critical patent/JPS61172822A/en
Publication of JPH0113691B2 publication Critical patent/JPH0113691B2/ja
Granted legal-status Critical Current

Links

Landscapes

  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

PURPOSE:To provide the titled preparation having excellent transintestinal absorbability and mitigated irritation and unagreeable feeling to the mouth and gastric mucosa in the administration of ionized calcium preparation, by adding reduced maltose and/or citric acid to ionized calcium of electrolyzed oyster shell. CONSTITUTION:The ionized calcium of electrolyzed oyster shell is a Ca preparation produced from electrolyzed oyster shell obtained by the electrolytic purification of oyster shell, and has remarkably high transintestinal absorbability compared with conventional Ca preparation. However, it has strong alkalinity and is liable to cause stimulation and nausea when administered in a empty stomach. It has been found that the disagreeable feeling of the ionized calcium of electrolyzed oyster shell can be mitigated without lowering the transintestinal absorbability of the ionized calcium by adjusting the pH of the preparation with reduced maltose and/or citric acid. The amounts of the reduced maltose and citric acid are preferably 0.3-3pts. and 1-2pts. per 1pt. of the ionized calcium of electrolyzed oyster shell.

Description

【発明の詳細な説明】 本発明は、イオン化カルシウムの服用時の口とか胃の粘
膜に対する刺激性、不快性を少なくした経口カルシウム
製剤に関する。
DETAILED DESCRIPTION OF THE INVENTION The present invention relates to an oral calcium preparation that reduces irritation and discomfort to the mucous membranes of the mouth and stomach when ionized calcium is taken.

カルシウムは丈夫な骨や歯をつくるだめの成分だけでな
く、血液の浄化や、脳、神経、心臓、筋肉など人間の生
命を維持してゆくのに重要な働きをしていることが、最
近の研究でつぎつぎと解明されている。
It has recently been discovered that calcium is not only a building block for strong bones and teeth, but also plays an important role in purifying the blood and maintaining human life in areas such as the brain, nerves, heart, and muscles. This has been elucidated one after another through research.

とくに成人病といわれる病気のほとんどが、カルシウム
などのミネラル不足や原因であると多くの学者が指摘し
ているし、厚生省の発表によっても、今日の一億半健康
の状態はカルシウムの不足に基因するものであることが
明らかになっている。
In particular, many scholars have pointed out that most of the so-called adult diseases are caused by a lack of minerals such as calcium, and the Ministry of Health and Welfare has also announced that the health status of 100 million and a half people today is due to a lack of calcium. It has become clear that it will.

人間の主なカルシウム補強源は、イオン化されたカルシ
ウムが含まれている牛乳や水などであるが、日本の水は
、日本国土産体が火山土質であるため、ヨーロッパの水
にくらべてb程度のカルシウムしか含まれていないため
、日本人は慢性的なカルシウム不足に陥シ、先に述べた
ような各機能に障害をもたらすことになる。
The main source of calcium supplementation for humans is milk and water, which contain ionized calcium, but since Japan's national treasure is made of volcanic soil, the water in Japan is only about B compared to water in Europe. Because it contains only 100% of calcium, Japanese people suffer from a chronic calcium deficiency, which leads to impairments in the various functions mentioned above.

そこで、この半健康状態を改善するには、カルシウムを
充分補うことが必要なのはいうまでもないが、カルシウ
ムを多く含んだ魚の骨や海草などを食べても、体内では
殆んど吸収されない。もともとカルシウムはイオンの状
態で存在する元素なので、体内でもイオン化しなければ
吸収されないからである。
Therefore, it goes without saying that to improve this semi-healthy state, it is necessary to supplement with sufficient calcium, but even if you eat fish bones and seaweed that contain a lot of calcium, very little of it is absorbed by the body. Calcium is an element that originally exists in the form of ions, so it cannot be absorbed by the body unless it is ionized.

カルシウム製剤についてはその吸収の機構が複雑である
ため、従来その剤形や製法にあまり工夫がなされていな
かったが、大量のカルシウムを有効に吸収させしかも不
快感を全く消失させるためには今后更にいくつかの問題
点を解決しなければならないとされていた。
Due to the complicated absorption mechanism of calcium preparations, not much effort has been made in the formulation or manufacturing method, but in order to effectively absorb large amounts of calcium and completely eliminate discomfort, more efforts have now been made. Several problems had to be resolved.

そこで、最近開発されだしたのが、イオン化されたカル
シウム製剤である。
Therefore, ionized calcium preparations have recently been developed.

本出願人も、この状況にかんがみ、先に牡蛎殻を電解精
製した電解ボレイを原料とし、その他のミネラルを含む
カルシウム製剤を開発した。
In view of this situation, the present applicant has previously developed a calcium preparation containing other minerals, using electrolytic borey obtained by electrolytically refining oyster shells as a raw material.

この電解ポレイイオン化カルシウムは財団法人 日本食
品分析センターによる電気伝導率の測定によって、イオ
ン化濃度が10,000μS/1117F!(25℃)
という高い測定値を示し、他の市販のカルシウム製剤の
イオン化濃度81〜790μS/α(25℃)にくらべ
抜群の腸内吸収性を示し、現在も各大学の付属病院をは
じめとする医療機関において、積極的にカルシウム不足
による病気の予防、治療に採用されている。
The ionization concentration of this electrolyzed polay ionized calcium was determined to be 10,000μS/1117F by measuring the electrical conductivity by the Japan Food Research Center Foundation! (25℃)
It has a high measurement value of 81 to 790μS/α (at 25℃) of other commercially available calcium preparations, and has excellent intestinal absorption, and is currently used in medical institutions such as university hospitals. It is actively used for the prevention and treatment of diseases caused by calcium deficiency.

電解ポレイイオン化カルシウムについての腸管吸収につ
いては、医療ジャーナル社発行「製薬工場」第4巻第1
2号(1984)に、神戸大学医学部第3内科藤田拓男
教授が報告されている。
Regarding the intestinal absorption of electrolyzed ionized calcium, please refer to "Pharmaceutical Factory", Vol. 4, No. 1, published by Medical Journal Co., Ltd.
No. 2 (1984), Professor Takuo Fujita of the Third Department of Internal Medicine, Kobe University School of Medicine reported.

ところで、この腸管吸収性のすぐれた電解ポレイイオン
化カルシウム製剤には、空腹時に服用すると人によって
は特に老人、胃弱者は刺激性を感じ、嘔吐窓を伴なうと
いう欠点があった。
However, this electropolymerized ionized calcium preparation, which has excellent intestinal absorption, has the disadvantage that when taken on an empty stomach, some people, especially the elderly and people with weak stomachs, may find it irritating and may be accompanied by a window of vomiting.

本発明者は、この原因が電解ボレイイオン化カルシウム
の強アルカリという、Hにあることをつきとめ、鋭意研
究を重ねた結果、本発明に到達したものである。
The present inventor found that the cause of this was due to H, which is a strong alkali of electrolytic ionized calcium, and as a result of extensive research, the present invention was achieved.

すなわち、PH10以上の強アルカリ性を示す電解ボレ
イイオン化カルシウムを服用し一度にとけると急に強い
アルカリ性になシ胃内の酸(PH1〜2)と急激に中和
反応を起こし、胃内の酸性状況がバランスを欠き、それ
が嘔吐窓、胃痛となって表われるものと考えられる。
In other words, if you take electrolyzed boley ionized calcium that is strongly alkaline with a pH of 10 or higher and dissolve it all at once, it will suddenly become strongly alkaline, causing a rapid neutralization reaction with the acid in the stomach (PH 1-2), and reducing the acidic situation in the stomach. This is thought to result in a lack of balance, which manifests itself in vomiting windows and stomach pain.

そこで電解ボレイイオン化カルシウムのPHを10〜4
程度の弱ア゛ルカリ性とし胃内で徐々にとかすか、急に
とけても中和させるようにすることにより嘔吐窓、胃痛
を伴うような変化は表われずに済むのではないかという
結論に至った0そこで、各種の、H調整剤を検討した結
果、電解ボレイイオン化カルシウムの腸管吸収性を低下
させることなく、PHを調整することのできるのは、還
元麦芽糖とクエン酸であることをつきとめ、本発明を完
成したものである。
Therefore, the pH of electrolytic boley ionized calcium was set to 10 to 4.
The conclusion was that by making it slightly alkaline and dissolving it gradually in the stomach, or neutralizing it even if it suddenly dissolves, changes such as the vomiting window and stomach pain may not occur. As a result of examining various H adjusters, we found that reduced maltose and citric acid can adjust the pH without reducing the intestinal absorption of electrolyzed ionized calcium. This has led to the completion of the present invention.

還元麦芽糖およびクエン酸の電解ボレイイオン化カルシ
ウムに対する配合割合(重量比)は、それほど厳密では
ないが、目安として電解ボレイイオン化カルシウム1に
対して還元麦芽糖の場合は0.5〜3、クエン酸の場合
は1〜2であることが好ましく、還元麦芽糖とクエン酸
を併用しても同様の効果が得られた。
The mixing ratio (weight ratio) of reduced maltose and citric acid to electrolytic boley ionized calcium is not very strict, but as a guide, it is 0.5 to 3 for reduced maltose and 0.5 to 3 for citric acid to 1 part electrolytic boley ionized calcium. is preferably 1 to 2, and similar effects were obtained even when reduced maltose and citric acid were used together.

処方例 l。Prescription example l.

電解ボレイイオン化カルシウム   30%(重量)粉
未還元麦芽糖          70%以上を加水混
合して造粒し、乾燥したのち錠剤機にて打錠する。
Electrolytic Borei ionized calcium 30% (by weight) Powder Unreduced maltose 70% or more is mixed with water, granulated, dried, and then tableted using a tablet machine.

処方例 2゜ 電解ポレイイオン化カルシウム50%に対して、粉未還
元麦芽糖を50%にし、処方lと同様にして打錠した。
Formulation Example 2゜Polymerized 50% ionized calcium and 50% powdered unreduced maltose were compressed into tablets in the same manner as in Formulation 1.

処方例 3゜ 電解ボレイイオン化カルシウム40%に対して、クエン
酸を60%にし、処方1と同様にして打錠した。
Formulation Example 3゜Electrolytic Borei 40% ionized calcium and 60% citric acid were compressed into tablets in the same manner as in Formulation 1.

処方例 4゜ 電解ボレイイオン化カルシウム33%に対して、粉未還
元麦芽糖を50%、クエン酸を17%にし、処方1と同
様にして打錠した。
Formulation Example 4゜Electrolytic Borei ionized calcium was 33%, powdered unreduced maltose was changed to 50%, and citric acid was changed to 17%, and the tablets were compressed in the same manner as in Formulation 1.

以上の処方により見られた電解ボレイイオン化カルシウ
ム製剤は、いずれも服用時に従来のような不快感が感じ
られなかった。
All of the electrolytic Borei ionized calcium preparations prepared according to the above formulations did not cause discomfort unlike conventional ones when taken.

特許出願人  株式会社 富士企画 手続補正書(自発差出) 昭和60年6月 4日 特許庁長官 志 賀    学 殿 1、事件の表示 昭和60年特許願第13608号 2、発明の名称 経口電解ボレイイオン化カルシウム製剤3、補正をする
者 事件との関係   特許出願人 住所 東京都渋谷区代々木5丁目59番4号名称   
株式会社 富 士 企 画 4、代理人 別紙記載の通り 7、 補正の内容 (1)明細書第1頁第18行「ミネラル不足や」を「ミ
ネラル不足が」と補正する。
Patent Applicant: Fuji Planning Co., Ltd. Written Amendment to Procedural Procedures (voluntarily submitted) June 4, 1985 Manabu Shiga, Director General of the Patent Office1, Indication of the Case 1985 Patent Application No. 136082, Name of the Invention Oral Electrolytic Boray Ionization Calcium Preparation 3, Relationship with the Amendment Case Patent Applicant Address 5-59-4 Yoyogi, Shibuya-ku, Tokyo Name
Fuji Planning Co., Ltd. 4. As stated in the agent's attachment 7. Contents of the amendment (1) On page 1, line 18 of the specification, "Mineral deficiency" is amended to read "Mineral deficiency."

(2)  同第2頁第4行「牛乳や水」を「牛乳や自然
な水」と補正する。
(2) On page 2, line 4, "milk and water" is corrected to "milk and natural water."

(3)  同第3頁第5行〜7行目「本出願人も・・・
開発した。」を「本出願人も、この状況にかんがみ、先
に牡端殻を電解精製したミネラルを含む電解ボレイイオ
ン化カルシウム製剤を開発した。」と補正する。
(3) Page 3, lines 5 to 7 “The applicant also...
developed. '' should be amended to ``In view of this situation, the present applicant has also developed an electrolytic boley ionized calcium preparation containing minerals obtained by electrolytically refining bull's-tail shells.''

(4)同第4頁第15〜16行目「そこで・・・・徐々
に」を「そこで電解ボレイイオン化カルシウムを徐々に
」と補正する。
(4) On page 4, lines 15 and 16, "there...gradually" is corrected to "gradually apply electrolytic ionized calcium there."

(5)同第5頁第15〜16行目「以上を・・・・打錠
する。」を「以上を一般の製剤方法により打錠する。」
と補正する。
(5) On page 5, lines 15 and 16, "the above is...compressed into tablets." is replaced with "the above is compressed into tablets using a general formulation method."
and correct it.

Claims (1)

【特許請求の範囲】[Claims] 電解ボレイイオン化カルシウムに還元麦芽糖および/ま
たはクエン酸を配合したことを特徴とする経口電解ボレ
イイオン化カルシウム製剤。
An oral electrolytic Borei ionized calcium preparation characterized by blending electrolytic Borei ionized calcium with reduced maltose and/or citric acid.
JP1360885A 1985-01-29 1985-01-29 Ionized calcium preparation for oral administration containing electrolyzed oyster shell Granted JPS61172822A (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP1360885A JPS61172822A (en) 1985-01-29 1985-01-29 Ionized calcium preparation for oral administration containing electrolyzed oyster shell

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP1360885A JPS61172822A (en) 1985-01-29 1985-01-29 Ionized calcium preparation for oral administration containing electrolyzed oyster shell

Publications (2)

Publication Number Publication Date
JPS61172822A true JPS61172822A (en) 1986-08-04
JPH0113691B2 JPH0113691B2 (en) 1989-03-07

Family

ID=11837941

Family Applications (1)

Application Number Title Priority Date Filing Date
JP1360885A Granted JPS61172822A (en) 1985-01-29 1985-01-29 Ionized calcium preparation for oral administration containing electrolyzed oyster shell

Country Status (1)

Country Link
JP (1) JPS61172822A (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS62263126A (en) * 1986-05-12 1987-11-16 Fuji Kikaku:Kk Ionized calcium preparation for oral administration produced from electrolyzed oyster shell

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5148467A (en) * 1974-10-23 1976-04-26 Kyoko Ootsu
JPS5585385A (en) * 1978-12-22 1980-06-27 Mitsuma Miyoshi Powdered food and drink
JPS5931710A (en) * 1982-08-17 1984-02-20 Masaki Takahara Drinking solution for supplying calcium

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5148467A (en) * 1974-10-23 1976-04-26 Kyoko Ootsu
JPS5585385A (en) * 1978-12-22 1980-06-27 Mitsuma Miyoshi Powdered food and drink
JPS5931710A (en) * 1982-08-17 1984-02-20 Masaki Takahara Drinking solution for supplying calcium

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS62263126A (en) * 1986-05-12 1987-11-16 Fuji Kikaku:Kk Ionized calcium preparation for oral administration produced from electrolyzed oyster shell
JPH0113692B2 (en) * 1986-05-12 1989-03-07 Fuji Kikaku Kk

Also Published As

Publication number Publication date
JPH0113691B2 (en) 1989-03-07

Similar Documents

Publication Publication Date Title
US5914129A (en) Analgesic composition for treatment of migraine headaches
US3337404A (en) Effervescent potassium composition
US20170080024A1 (en) Effervescent gargle tablet and method of using same
US4959222A (en) Magnesium additive for nutrients, feed, and medicaments
US4387093A (en) Arthritis treatment
JPH06506682A (en) Oral pharmaceutical composition for treating upper gastrointestinal tract symptoms
ES2192136B1 (en) PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OR PREVENTION OF OSTEOPOROSIS.
JPH09183732A (en) Potassium dominant non-solution pill and health promotion using the pill
JPS61172822A (en) Ionized calcium preparation for oral administration containing electrolyzed oyster shell
US4539315A (en) Sublingually absorbable nontoxic aspirin composition
JPH0563452B2 (en)
US4650668A (en) Composition for relieving toothache pain and other forms of intense pain
JPS62263126A (en) Ionized calcium preparation for oral administration produced from electrolyzed oyster shell
US4446132A (en) Nontoxic aspirin composition
RU2176893C2 (en) Biologically active food supplement "dnaavit"
JP2665764B2 (en) Calcium aqueous solution
JP6355806B1 (en) A therapeutic agent for constipation containing lactulose as an active ingredient
JP2002201135A (en) Composition for epigastrium comprising lactulose
RU2205648C1 (en) "calcisan" composition for prophylaxis and maintenance therapy in case of gastro-intestinal diseases
RU2026673C1 (en) Agent for enuresis treatment
RU1804850C (en) Method for treatment influenza
Van Dyke Medical problems in infants and young children with Down syndrome: Implications for early services
Srilakshmi et al. INTERNATIONAL RESEARCH JOURNAL OF PHARMACY
UA141902U (en) METHOD OF CORRECTION OF MAGNESIUM DEFICIENCY IN THE BODY DURING MASSAGE PROCEDURE
KR20200083971A (en) Calcium supplement composition

Legal Events

Date Code Title Description
EXPY Cancellation because of completion of term